On December 10, 2014, the US Food and Drug Administration (FDA) approved Gardasil 9 (Human Papillomavirus [HPV] 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by 9 types of HPV.
On December 10, 2014, the US Food and Drug Administration (FDA) approved Gardasil 9 (Human Papillomavirus [HPV] 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by 9 types of HPV. The new vaccine covers 5 more HPV types than the previously approved Gardasil and can potentially prevent 90% of cervical, vulvar, vaginal, and anal cancers.
Point/Counterpoint: Is HPV testing ready for 'prime time'?
Gardasil 9 is approved for use in females ages 9 to 26 years and males ages 9 to 15 years for prevention of vulvar, vaginal, anal, and cervical cancers caused by HPV types 16, 18, 33, 45, 52, and 58. It will also prevent genital warts caused by HPV types 6 and 11. The additional 5 HPV types -31, 33, 45, 52 and 58- are the cause of roughly 20% of cervical cancers.
FDA approval was based on results of a study involving roughly 14,000 HPV-negative women ages 16 to 26 years who received either Gardasil or Gardasil 9. Gardasil 9 was found to be 97% effective in preventing vaginal, vulvar, and cervical cancers caused by the 5 new HPV types and as effective as Gardasil in preventing HPV types 6, 11, 16, and 18.
Antibody response rates in approximately 2800 females and 1200 males ages 9 to 15 were similar to those in females ages 16 through 26, leading to the conclusion that the vaccine would be similarly effective in the younger age group. Due to low incidence of anal cancer caused by the 5 new HPV types, the indication for prevention of anal cancer is based on Gardasil’s demonstrated effectiveness and additional data on antibodies in males and females who received Gardasil 9.
Gardasil 9’s safety was evaluated in approximately 13,000 males and females, with the most common adverse reactions reported being headaches, redness, swelling, and injection site pain.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
PCOS and irregular cycles tied to cardiometabolic risks
May 15th 2024A comprehensive analysis reveals strong associations between polycystic ovary syndrome, irregular menstrual cycles, and increased risks of cardiometabolic conditions, underscoring the importance of proactive screening and intervention strategies.
Read More
Postmenopausal urinary incontinence treatment data found lacking
May 6th 2024Discover the findings of a comprehensive study exploring the efficacy of various treatments for postmenopausal urinary incontinence, shedding light on the current research gap and recommending avenues for future investigation.
Read More
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
Advancing obstetric and gynecologic surgery through robotic innovation
April 30th 2024Explore how robotic surgery revolutionizes obstetric and gynecologic procedures, offering enhanced precision, reduced complications, and improved patient outcomes, while also examining challenges and future prospects in the field.
Read More